F-18 FDOPA PET: A Multi-Target Tracer

F-18 FDOPA (fluorodopa F 18) is one of the most versatile positron-emitting tracers in clinical use: a fluorinated analog of the amino acid L-DOPA that images dopaminergic nerve terminals in the brain and amino-acid transport in tumors. That single molecule supports evaluation of parkinsonian syndromes, neuroendocrine tumors, congenital hyperinsulinism, and gliomas — four very different clinical problems that share one biochemistry.¹²

Because the biology, the premedication decision, the imaging protocol, the quantification, and the interpretation all differ by indication, a defensible FDOPA program is really several protocols hiding under one tracer name. This guide explains the physics and biochemistry, walks through the major indications, and covers the carbidopa decision, quantification, dosimetry, production, and regulatory context a nuclear medicine physics program should understand.²

Introduction

Most clinical PET runs on a single workhorse, F-18 FDG, which maps glucose metabolism. FDOPA is the counterexample: a tracer whose value comes precisely from not being a metabolic marker. It is a targeted amino-acid tracer, and its uptake reflects the machinery cells use to import and decarboxylate aromatic amino acids. That machinery is prominent in dopaminergic neurons and in a range of neuroendocrine and neuro-oncologic tissues, which is why one molecule reaches across so many indications.¹²

For the imaging physicist and the nuclear medicine team, FDOPA is interesting for a second reason: it forces the discipline to treat "the tracer" and "the protocol" as separate things. The same F-18 FDOPA that gives a parkinsonism study its striatal binding ratio gives a neuroendocrine study its tumor-to-background contrast only when the patient has been prepared and imaged correctly for that indication. Get the biochemistry right and FDOPA is a powerful problem-solver; treat it as a generic PET agent and it disappoints.

This article covers the tracer's physics, its mechanism, its clinical uses, the carbidopa premedication question, quantification, dosimetry, production, and the regulatory frame. DRPS supports PET programs adopting or optimizing specialized tracers through PET/CT and nuclear medicine physics and medical physicist consulting across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

The tracer and its physics

FDOPA is labeled with fluorine-18, the same positron emitter that powers FDG. F-18 decays predominantly by positron emission with a physical half-life of about 109.7 minutes (roughly 110 minutes), and the emitted positron annihilates with an electron to produce the pair of 511 keV photons that PET detects in coincidence. The relatively low maximum positron energy of F-18 gives a short positron range and correspondingly good intrinsic spatial resolution, which is one reason F-18 tracers are preferred when the target is small — such as the striatum or a millimeter-scale focal pancreatic lesion.¹

The 110-minute half-life shapes logistics: FDOPA must be produced in a cyclotron-equipped radiopharmacy and delivered on a schedule, and — as discussed below — its more demanding synthesis makes it less widely available than FDG. For the physics of on-site F-18 production, see our overview of cyclotron F-18 production.

The mechanism: amino-acid transport and decarboxylation

FDOPA is a large neutral amino acid. It enters cells through the system L amino acid transporter (LAT1), which is upregulated in many tumors and is the basis for amino-acid PET in neuro-oncology. Inside dopaminergic neurons, FDOPA is decarboxylated by aromatic amino acid decarboxylase (AADC) to F-18 fluorodopamine, which is stored in synaptic vesicles and trapped. The density of functioning presynaptic dopaminergic terminals therefore determines striatal FDOPA uptake, making it a marker of nigrostriatal integrity.¹²

The same decarboxylation pathway is active in neuroendocrine cells, which take up and decarboxylate amine precursors. That shared biochemistry is why one tracer serves both the movement-disorder clinic and the neuroendocrine tumor board.²

Key Technical Principles

One tracer, several protocols

The table below summarizes how FDOPA is applied across its major indications. The protocol details — premedication, timing, and the primary metric — are what differ, not the tracer.¹²³⁴

Indication	What FDOPA reflects	Carbidopa premedication	Primary metric
Parkinsonian syndromes	Presynaptic dopaminergic terminal density in the striatum	Generally not used for brain dopaminergic imaging	Striatal specific uptake ratio; regional pattern (caudate vs putamen)
Neuroendocrine tumors, pheochromocytoma/paraganglioma	Amino-acid uptake and decarboxylation in tumor cells	Commonly used to raise tumor-to-background	Tumor-to-background ratio; lesion detection
Congenital hyperinsulinism	Uptake in insulin-secreting pancreatic tissue	Commonly used	Focal versus diffuse uptake pattern for surgical planning
Glioma grading / restaging	LAT1-mediated amino-acid transport in tumor	Variable by protocol	Tumor-to-normal-brain and tumor-to-striatum ratios

The clinical lesson is that a program cannot run "an FDOPA scan." It runs a parkinsonism protocol, a neuroendocrine protocol, a hyperinsulinism protocol, or a neuro-oncology protocol, each with its own preparation and interpretation.

Quantifying dopaminergic imaging

For brain dopaminergic imaging, the workhorse metric is a striatal specific uptake ratio (SUr) that compares specific striatal binding to a non-specific reference region such as the occipital cortex:

SUr = \frac{C _{striatum} - C _{ref}}{C _{ref}}

where $C_{striatum}$ is the striatal (or subregional caudate/putamen) concentration and $C_{ref}$ is the reference-region concentration. A reduced, spatially patterned SUr — classically posterior putamen first — supports a neurodegenerative parkinsonian syndrome.¹

When a dynamic acquisition with an input function is available, the tracer's irreversible trapping is well described by Patlak graphical analysis, which yields the uptake rate constant $K_{i}$ :

\frac{C _{tissue} ( t )}{C _{p} ( t )} = K_{i} \frac{\int _{0}^{t} C _{p} ( τ ) d τ}{C _{p} ( t )} + V_{0}

Here $C_{tissue} (t)$ is the tissue activity concentration, $C_{p} (t)$ the plasma (or image-derived) input concentration, and $V_{0}$ an intercept term. Because FDOPA is effectively trapped after decarboxylation over the imaging window, a plot of $C_{tissue} / C_{p}$ against the "Patlak time" becomes linear, and its slope is $K_{i}$ — a quantitative index of dopaminergic function. Advances such as large-axial-field-of-view PET make image-derived input functions and this kind of quantification more practical.¹ For the broader principles of PET quantification, see our guide to SUV quantification.

Dosimetry: putting a number on the dose

Patient dose from FDOPA is estimated the same way as any radiopharmaceutical — the administered activity multiplied by an effective-dose coefficient:

E = c_{E} \cdot A

For F-18 FDOPA, the effective-dose coefficient is on the order of $0.02 mSv \cdot MB q^{- 1}$ , with the urinary bladder wall typically the organ receiving the highest absorbed dose (roughly $0.15 mGy \cdot MB q^{- 1}$ ).⁵⁶ For a representative adult administered activity of about $250 MBq$ :

E \approx 0.02 \frac{mSv}{MBq} \times 250 MBq \approx 5 mSv

That is a low-single-digit millisievert dose from the tracer itself; a co-acquired CT adds its own dose depending on the protocol. Administered activity for FDOPA is often weight-based, on the order of $4 MBq \cdot k g^{- 1}$ , or a fixed adult activity in the roughly $185$ to $370 MBq$ range, following the approved labeling and society guidance; hydration and voiding reduce bladder dose because the bladder is the critical organ.⁵⁶ For a deeper treatment of internal dose methodology, see radiopharmaceutical dosimetry and ICRP 128.

Clinical Impact

Parkinsonian syndromes

FDOPA received U.S. Food and Drug Administration approval in 2019 as a diagnostic agent to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected parkinsonian syndromes.⁵ Reduced, regionally patterned striatal uptake supports a neurodegenerative parkinsonian process and helps distinguish it from conditions such as essential tremor or drug-induced parkinsonism. FDOPA PET is complementary to dopamine-transporter SPECT imaging; for the SPECT approach, see our post on DaTscan I-123 ioflupane SPECT.

Neuroendocrine tumors

FDOPA images the amino-acid uptake and decarboxylation of neuroendocrine cells, making it useful in well-differentiated neuroendocrine tumors, pheochromocytoma, and paraganglioma, particularly in specific genetic and anatomic subsets where it can outperform other tracers.² It sits alongside somatostatin-receptor imaging in the neuroendocrine work-up — see Ga-68 DOTATATE PET for neuroendocrine tumors — with tracer choice guided by tumor type, differentiation, and the clinical question.

Congenital hyperinsulinism

In infants with congenital hyperinsulinism unresponsive to medical therapy, F-18 FDOPA PET/CT is the imaging method of choice to distinguish a focal lesion, which can be cured by limited pancreatectomy, from diffuse disease, which is managed differently. Correctly localizing a focal lesion can spare an infant a near-total pancreatectomy, so the study directly changes surgery.³ This indication also illustrates the dose-stewardship imperative in a highly radiosensitive population, where new detector technology and careful protocol design help minimize administered activity.

Gliomas and neuro-oncology

As an amino-acid tracer taken up via LAT1, FDOPA helps grade gliomas, distinguish tumor recurrence from treatment-related change, and target biopsy or radiotherapy — questions where contrast-enhanced MRI and FDG are limited. FDOPA can highlight areas of higher-grade transformation and delineate tumor beyond contrast enhancement, complementing MRI in the framework of amino-acid PET recommendations for neuro-oncology.⁴ For brain FDG's distinct role, see brain FDG PET in dementia and epilepsy.

Practical Optimization Tips

1. Choose the protocol before the tracer arrives

Decide the indication-specific protocol — premedication, timing, dynamic versus static, and the intended metric — at scheduling, not at injection. FDOPA's value collapses if a neuroendocrine patient is imaged with a brain protocol or vice versa.

2. Make the carbidopa decision deliberately

Carbidopa premedication inhibits peripheral AADC, cutting physiologic pancreatic and background uptake and improving tumor-to-background for neuroendocrine and hyperinsulinism imaging.²³ Standardize whether, when, and how much carbidopa is given for each indication, and record it, because it changes biodistribution and therefore interpretation.

3. Standardize timing and reconstruction for quantification

If a program reports striatal ratios, SUV-based tumor metrics, or $K_{i}$ , then uptake time, acquisition window, and reconstruction must be held constant. A ratio or SUV is only comparable across patients and across time when the protocol is fixed — the same discipline that underlies all quantitative PET.

4. Manage dose in sensitive populations

For pediatric and infant hyperinsulinism imaging, weight-based dosing, modern reconstruction, and voiding/hydration to reduce bladder dose all matter, since the bladder wall is the critical organ.⁵⁶ Confirm that pediatric administered-activity guidance is followed.

5. Verify quantification tools before clinical reliance

Any semiquantitative software — striatal analysis packages, normal databases, SUV workflows — should be validated on your scanner and reconstruction before it informs clinical decisions, with harmonization where a normal reference database is used.¹

Common pitfalls to avoid

Treating FDOPA as a generic PET tracer. The protocol is indication-specific.
Inconsistent carbidopa use. Undocumented premedication undermines interpretation and comparison.
Drifting uptake times or reconstructions. These break quantitative comparability.
Ignoring the bladder. It is the critical organ; hydration and voiding reduce dose.
Assuming universal availability. FDOPA's synthesis and CGMP production limit supply relative to FDG.

Regulatory Considerations

FDOPA is a manufactured PET drug and a byproduct-material radiopharmaceutical, so it sits at the intersection of FDA drug regulation and NRC or Agreement State materials regulation. A program should treat both.

FDA drug approval and labeling. Fluorodopa F 18 Injection is FDA-approved (NDA 200655, 2019) for visualizing striatal dopaminergic nerve terminals in suspected parkinsonian syndromes; the approved prescribing information governs the labeled indication, administered activity, and dosimetry.⁵ Uses in neuroendocrine tumors, congenital hyperinsulinism, and gliomas are established in the literature and practiced under applicable institutional and regulatory pathways.²³⁴
PET drug manufacturing. PET drugs are produced under current good manufacturing practice for PET drugs in 21 CFR Part 212, with compounding and quality standards reflected in USP chapters for PET radiopharmaceuticals. This is part of why FDOPA availability is more constrained than FDG.⁷⁸
Medical use and radiation safety. As byproduct material, FDOPA administration falls under 10 CFR Part 35 (medical use) and the radiation protection standards of 10 CFR Part 20, or the equivalent Agreement State rules.⁹¹⁰ Among the states DRPS serves, Florida, Maryland, Virginia, California, and Nevada are NRC Agreement States administering their own programs, while Washington DC is regulated directly by the NRC. A facility must verify which authority issues and inspects its license.

Programs adopting FDOPA should confirm authorized-user coverage, dosimetry and administered-activity records, and quality controls, and coordinate the addition with radioactive material license support and their radiation safety program. Diagnostic PET does not require a written directive, but the general Part 35 framework and Part 20 dose limits still apply.

Frequently Asked Questions (FAQs)

What is F-18 FDOPA and how does it work?

F-18 FDOPA (fluorodopa F 18) is a positron-emitting radiopharmaceutical, a fluorinated analog of the amino acid L-DOPA. It enters cells through the large neutral amino acid transporter (LAT1) and, in dopaminergic neurons, is decarboxylated by aromatic amino acid decarboxylase (AADC) to F-18 dopamine and trapped. This lets it image both presynaptic dopaminergic function in the brain and amino-acid handling in tumors.

What is F-18 FDOPA PET used for?

FDOPA PET has multiple approved and established uses: evaluating parkinsonian syndromes by imaging striatal dopaminergic nerve terminals, imaging neuroendocrine tumors and pheochromocytoma/paraganglioma, localizing focal versus diffuse disease in congenital hyperinsulinism, and grading or restaging gliomas as an amino-acid brain tumor tracer.

Why is carbidopa given before some FDOPA scans?

Oral carbidopa premedication inhibits peripheral aromatic amino acid decarboxylase, which reduces physiologic pancreatic and background uptake and increases tumor-to-background contrast. It is commonly used for neuroendocrine tumor and congenital hyperinsulinism imaging, but its use and timing depend on the indication and local protocol.

How much radiation dose does an FDOPA PET scan give?

F-18 FDOPA has an effective dose coefficient on the order of 0.02 mSv per MBq, with the urinary bladder wall typically the organ receiving the highest absorbed dose. A representative adult administered activity therefore delivers an effective dose in the low-single-digit millisievert range from the tracer, plus any dose from an accompanying CT.

Is FDOPA the same as an FDG PET scan?

No. FDG images glucose metabolism, while FDOPA images amino-acid transport and, in the brain, dopaminergic terminal function. For neuroendocrine tumors, gliomas, and parkinsonism, FDOPA and other targeted tracers often outperform FDG, which is why FDOPA occupies a distinct niche in the PET tracer landscape.

Why is FDOPA harder to produce than FDG?

FDOPA synthesis is more complex than FDG. Historical electrophilic fluorination produced low molar activity, while modern nucleophilic routes achieve higher molar activity and yield but require robust radiochemistry. As a PET drug it is produced under 21 CFR Part 212 current good manufacturing practice, which contributes to limited availability compared with FDG.

How is FDOPA uptake quantified?

For brain dopaminergic imaging, a striatal specific uptake ratio is commonly computed relative to a non-specific reference region such as the occipital cortex. Dynamic acquisitions can also yield the uptake rate constant Ki using Patlak graphical analysis. For tumors, SUV-based metrics and tumor-to-background ratios are used, always with attention to consistent protocol and reconstruction.

Key Takeaways

One molecule, many targets. FDOPA images amino-acid transport and decarboxylation, serving parkinsonism, neuroendocrine tumors, congenital hyperinsulinism, and gliomas.¹²
The protocol is indication-specific. Premedication, timing, and metric differ by use; there is no single "FDOPA scan."
Carbidopa is a deliberate choice. It improves tumor-to-background for neuroendocrine and hyperinsulinism imaging and must be documented.²³
Physics favors small targets. The short positron range of F-18 and its ~110-minute half-life support high-resolution imaging of the striatum and small focal lesions.¹
Dose is modest but the bladder leads. The effective-dose coefficient is about 0.02 mSv/MBq with the bladder wall as the critical organ; hydration and voiding help.⁵⁶
Availability is constrained. Demanding CGMP synthesis makes FDOPA less widely available than FDG, a planning reality for adopting programs.⁷

Conclusion

F-18 FDOPA is a reminder that in molecular imaging the biology is the modality. A single fluorinated amino acid, by tracing the transport-and-decarboxylation pathway, reaches from the movement-disorder clinic to the neuroendocrine tumor board to the infant with hyperinsulinism to the neuro-oncology suite.¹²³⁴ That versatility is a gift and a discipline: the tracer only performs when the protocol, premedication, timing, and quantification are matched to the specific clinical question.

For a nuclear medicine physics program, FDOPA rewards the same rigor that underlies all quantitative PET — fixed protocols, validated quantification, deliberate dose stewardship in sensitive populations, and clear regulatory footing as both an FDA-approved drug and byproduct material. Handled that way, FDOPA is one of the most powerful problem-solvers in the PET toolkit.

How DRPS Can Help

Diagnostic Radiation Physics Services helps PET/CT programs adopt and optimize specialized tracers like FDOPA with defensible physics and documentation. This can include protocol design and validation for each indication, quantification and reconstruction setup, dose optimization for pediatric and adult patients, image-quality and scanner performance verification, and license and radiation-safety coordination through PET/CT and nuclear medicine physics, medical physicist consulting, and radioactive material license support.

DRPS supports nuclear medicine and PET facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A specialized tracer is only as good as the protocol behind it — that is where physics support pays off.

Related Resources

References

Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(8):1885-1912. doi:10.1007/s00259-020-04817-8. PubMed
Stormezand GN, de Meyer E, Koopmans KP, Brouwers AH, Luurtsema G, Dierckx RAJO. Update on the role of [18F]FDOPA PET/CT. Seminars in Nuclear Medicine. 2024;54(6):845-855. doi:10.1053/j.semnuclmed.2024.09.004. PubMed
States LJ, Davis JC, Hamel SM, Becker SA, Zhuang H. 18F-6-fluoro-L-dopa PET/CT imaging of congenital hyperinsulinism. Journal of Nuclear Medicine. 2021;62(Suppl 2):51S-56S. doi:10.2967/jnumed.120.246033. PubMed
Roach JR, Plaha P, McGowan DR, Higgins GS. The role of [18F]fluorodopa positron emission tomography in grading of gliomas. Journal of Neuro-Oncology. 2022;160(3):577-589. doi:10.1007/s11060-022-04177-3. PubMed
U.S. Food and Drug Administration. Fluorodopa F 18 Injection — Prescribing Information (NDA 200655). 2019. DailyMed
International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Annals of the ICRP. 2015;44(2 Suppl). icrp.org
U.S. Food and Drug Administration. 21 CFR Part 212: Current Good Manufacturing Practice for Positron Emission Tomography Drugs. ecfr.gov
United States Pharmacopeia. General Chapter <823> Positron Emission Tomography Drugs for Compounding, Investigational, and Research Uses. usp.org
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov